source
- Philips earmarks $322 million for pending DOJ settlement on sleep-apnea device recallPhilips' Respironics division announced it has reached an agreement in principle with the U.S. Department of Justice to settle the investigation into its sleep‑apnea device recall. The recall, ini…
- Pfizer drops phase 2 pulmonary arterial hypertension candidate amid pipeline cutPfizer has discontinued its phase 2 pulmonary arterial hypertension (PAH) program, PF-07868489, citing business reasons rather than safety or efficacy concerns. The drug, which targets BMP9 inhibi…